Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RPRX

Royalty Pharma plc

Feb 11 • 04:00PM ET

44.25

+0.04 0.09 %

Healthcare • Biotechnology • USA • NASD

Today, 2:15 PMRoyalty Pharma beats in Q4 2025 with non-GAAP EPS $1.47 (+27% YoY) and revenue $874M (+18%) as Royalty Receipts rise 17%, guides 2026 Portfolio Receipts growth of 3–8%, raises its quarterly dividend 7% to $0.235, and expects 2026 operating/professional costs to fall to 5%–6.5% of receipts from 8.9% after internalizing its external manager. It also disclosed repurchasing 37M shares for $1.2B in 2025, returning $1.7B to shareholders and hitting its five-year $10–$12B capital deployment goal a year early.

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VFLO VXF IWR VYM SCHM IHE IWD COWG DGRO IWS

Scroll to Statements

Index	-	P/E	25.30	EPS (ttm)	1.75	Insider Own	8.98%	Shs Outstand	429.03M	Perf Week	1.30%
Market Cap	25.54B	Forward P/E	8.35	EPS next Y	5.30	Insider Trans	-2.43%	Shs Float	388.86M	Perf Month	9.91%
Enterprise Value	36.76B	PEG	0.96	EPS next Q	1.09	Inst Own	80.35%	Short Float	6.81%	Perf Quarter	14.82%
Income	764.74M	P/S	10.87	EPS this Y	-0.62%	Inst Trans	3.19%	Short Ratio	6.67	Perf Half Y	23.40%
Sales	2.35B	P/B	2.96	EPS next Y	10.40%	ROA	4.09%	Short Interest	26.46M	Perf YTD	14.52%
Book/sh	14.95	P/C	26.75	EPS next 5Y	8.68%	ROE	11.51%	52W High	44.92 -1.50%	Perf Year	37.21%
Cash/sh	1.65	P/FCF	10.18	EPS past 3/5Y	8.57% -21.51%	ROIC	5.10%	52W Low	29.66 49.19%	Perf 3Y	16.14%
Dividend Est.	0.98 (2.23%)	EV/EBITDA	23.97	Sales past 3/5Y	-0.38% 4.52%	Gross Margin	-	Volatility	1.92% 1.68%	Perf 5Y	-6.47%
Dividend TTM	0.88 (1.99%)	EV/Sales	15.64	EPS Y/Y TTM	-31.46%	Oper. Margin	65.19%	ATR (14)	0.90	Perf 10Y	-
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	3.48	Sales Y/Y TTM	3.72%	Profit Margin	32.54%	RSI (14)	73.48	Recom	1.27
Dividend Gr. 3/5Y	7.30% -	Current Ratio	3.48	EPS Q/Q	-45.18%	SMA20	6.21%	Beta	0.41	Target Price	49.86
Payout	43.94%	Debt/Eq	1.40	Sales Q/Q	7.90%	SMA50	10.04%	Rel Volume	1.31	Prev Close	44.21
Employees	99	LT Debt/Eq	1.34	Earnings	Feb 11 BMO	SMA200	19.69%	Avg Volume	3.97M	Price	44.25
IPO	Jun 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.02% 8.31%	Trades		Volume	5,204,820	Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	UBS	Neutral → Buy	$49
Sep-30-25	Initiated	Goldman	Buy	$42
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50

Show Previous Ratings

Today 02:02PM	Royalty Pharma PLC (RPRX) Q4 2025 Earnings Call Highlights: Strong Growth and Strategic Capital ... (GuruFocus.com)
12:32PM	Royalty Pharma plc Q4 2025 Earnings Call Summary (Moby)
09:52AM	Royalty Pharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings (Zacks)
07:32AM	Royalty Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:25AM	Loading…
07:25AM	Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings (StockStory)
07:00AM	Royalty Pharma Reports Q4 and Full Year 2025 Results (GlobeNewswire)
Feb-10-26 09:15AM	Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
06:41AM	UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) - Here's Why (Insider Monkey)
Feb-09-26 10:06PM	What To Expect From Royalty Pharma's (RPRX) Q4 Earnings (StockStory)
Feb-05-26 11:38PM	3 Mid-Cap Stocks We Keep Off Our Radar (StockStory)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-24-26 06:37AM	Jim Cramer on Royalty Pharma: "It's a Terrific Company" (Insider Monkey)
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
08:53PM	Loading…
Jan-22-26 08:53PM	Lightning Round: Coherent is a winner, says Jim Cramer (CNBC TV)
Jan-20-26 04:15PM	Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (GlobeNewswire)
Jan-12-26 12:26PM	Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug (Benzinga)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
07:15AM	Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-11-26 05:15PM	Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire)
Jan-09-26 08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
08:30AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
01:52AM	Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal - Stock Soars Overnight (Benzinga)
Jan-07-26 10:37PM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) (StockStory)
Dec-29-25 04:40PM	Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones (GlobeNewswire)
Dec-16-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
07:05AM	Loading…
07:05AM	Denali makes $275m funding agreement with Royalty Pharma (Pharmaceutical Business Review)
Dec-04-25 07:10AM	Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement (GlobeNewswire)
Nov-26-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-24-25 06:12AM	Vaximm and BCME link on oral cancer immunotherapy platform (Pharmaceutical Technology)
Nov-14-25 12:56PM	Eli Lilly Leads Three Stocks Near Buy Points (Investor's Business Daily)
Nov-12-25 11:03PM	Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research) +6.82%
02:03PM	Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... (GuruFocus.com)
09:30AM	Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:23AM	Royalty Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences (GlobeNewswire)
Nov-03-25 10:34PM	Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
10:15PM	What To Expect From Royalty Pharma's (RPRX) Q3 Earnings (StockStory)
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Avoid RPRX and 1 Stock to Buy Instead (StockStory)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat)
12:24PM	What Do Analysts Think About Royalty Pharma Plc (RPRX)? (Insider Monkey)
Oct-17-25 09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:15AM	Royalty Pharma Declares Fourth Quarter 2025 Dividend (GlobeNewswire)
Oct-14-25 07:45AM	Kailera nets $600M more to advance Zepbound-like obesity drug (BioPharma Dive)
Oct-09-25 04:15PM	Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-08-25 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Sep-29-25 08:15AM	Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director (GlobeNewswire)
Sep-23-25 07:10PM	Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth (Insider Monkey)
Sep-19-25 04:25PM	Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum (GlobeNewswire)
Sep-17-25 02:27PM	TD Cowen Maintains a Buy on Royalty Pharma (RPRX) (Insider Monkey)
12:43AM	1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore (StockStory)
Sep-16-25 09:28AM	Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts (Insider Monkey)
Sep-11-25 11:13AM	Royalty Pharma plc (RPRX) Commits $300M to Zenas' Obexelimab Program (Insider Monkey)
07:00AM	Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation (GlobeNewswire)
Sep-10-25 07:30AM	Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market (GlobeNewswire)
Sep-04-25 04:15PM	Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Sep-02-25 08:30PM	Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes (GlobeNewswire)
07:15AM	Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million (GlobeNewswire)
Aug-29-25 02:57PM	Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase (Insider Monkey)
05:05AM	Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal (Insider Monkey)
04:54AM	Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines (Insider Monkey)
Aug-25-25 01:19PM	BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up (Benzinga)
08:29AM	Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales (BioPharma Dive)
06:33AM	Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters)
06:10AM	Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million (GlobeNewswire)
06:00AM	BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million (Business Wire)
Aug-13-25 04:15PM	Henry Fernandez Steps Down from Royalty Pharma's Board of Directors (GlobeNewswire)
01:35AM	5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call (StockStory)
Aug-12-25 09:10AM	Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT (Insider Monkey)
03:18AM	RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments (StockStory)
Aug-10-25 11:31PM	Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) (StockStory)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings (Zacks)
08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
08:08AM	Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates (StockStory)
07:22AM	Royalty Pharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:15AM	Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Aug-04-25 11:21PM	Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow (StockStory)
Jul-30-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Watch RPRX and 1 to Stay Cautious (StockStory)
Jul-18-25 08:15AM	Royalty Pharma Declares Third Quarter 2025 Dividend (GlobeNewswire)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors (GlobeNewswire)
Jul-16-25 04:15PM	Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
Jun-27-25 08:33AM	5 Revealing Analyst Questions From Royalty Pharma's Q1 Earnings Call (StockStory)
Jun-24-25 07:05AM	Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion (GlobeNewswire)
Jun-18-25 11:39PM	Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks (StockStory)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coyne Terrance P.	EVP & CFO	Feb 03 '26	Sale	42.84	114,954	4,924,997	23,972	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 02 '26	Sale	42.08	108,424	4,562,905	30,167	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 04 '26	Sale	43.29	20,163	872,913	22,885	Feb 04 05:07 PM
Terrance Coyne	Officer	Feb 03 '26	Proposed Sale	42.97	135,117	5,805,977		Feb 03 05:31 PM
Terrance Coyne	Officer	Feb 02 '26	Proposed Sale	42.36	108,424	4,592,841		Feb 02 05:28 PM
Urist Marshall	EVP, Research & Investments	Jan 30 '26	Sale	41.09	20,000	821,810	0	Feb 02 04:59 PM
Urist Marshall	EVP, Research & Investments	Jan 23 '26	Sale	40.26	20,000	805,110	20,000	Jan 26 04:10 PM
Coyne Terrance P.	EVP & CFO	Jan 20 '26	Sale	39.35	69,582	2,737,940	36,010	Jan 23 04:48 PM
Urist Marshall	EVP, Research & Investments	Jan 16 '26	Sale	39.52	20,000	790,346	40,000	Jan 20 05:00 PM
Terrance Coyne	Officer	Jan 20 '26	Proposed Sale	39.09	69,582	2,719,960		Jan 20 04:55 PM
Urist Marshall	EVP, Research & Investments	Jan 09 '26	Sale	40.78	20,000	815,634	60,000	Jan 13 05:37 PM
George Lloyd	Officer	Jan 07 '26	Proposed Sale	41.39	495,860	20,523,645		Jan 07 05:03 PM
Coyne Terrance P.	EVP & CFO	Jan 02 '26	Sale	38.42	69,582	2,673,041	39,760	Jan 06 04:18 PM
Urist Marshall	EVP, Research & Investments	Jan 02 '26	Sale	38.48	20,000	769,650	80,000	Jan 06 04:17 PM
Terrance Coyne	Officer	Jan 02 '26	Proposed Sale	38.86	69,582	2,703,957		Jan 02 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 26 '25	Sale	39.32	20,000	786,380	100,000	Dec 29 04:58 PM
Urist Marshall	EVP, Research & Investments	Dec 19 '25	Sale	38.38	20,000	767,582	120,000	Dec 22 04:09 PM
Lloyd George W.	EVP, Investments & CLO	Dec 17 '25	Sale	38.57	79,346	3,060,280	30,654	Dec 19 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Dec 18 '25	Sale	38.50	30,654	1,180,053	0	Dec 19 05:24 PM
Urist Marshall	EVP, Research & Investments	Dec 16 '25	Sale	38.32	20,000	766,420	140,000	Dec 17 05:43 PM
Coyne Terrance P.	EVP & CFO	Dec 15 '25	Sale	38.36	69,582	2,669,172	43,510	Dec 17 05:39 PM
Sandy Lamm LLC	Officer	Dec 16 '25	Proposed Sale	38.36	160,000	6,137,600		Dec 16 09:41 PM
Terrance Coyne	Officer	Dec 15 '25	Proposed Sale	38.53	69,582	2,680,994		Dec 15 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	23,334	913,591	160,000	Dec 09 05:00 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	18,242	714,224	7,398	Dec 09 05:00 PM
Lloyd George W.	EVP, Investments & CLO	Dec 03 '25	Sale	39.77	110,000	4,375,008	110,000	Dec 05 05:01 PM
Coyne Terrance P.	EVP & CFO	Dec 01 '25	Sale	39.87	69,582	2,773,956	47,260	Dec 03 05:11 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.93	23,333	931,633	183,334	Dec 03 05:10 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.90	18,242	727,856	25,640	Dec 03 05:10 PM
Terrance Coyne	Officer	Dec 01 '25	Proposed Sale	39.90	69,582	2,776,322		Dec 01 05:53 PM
Urist Marshall	Officer	Dec 01 '25	Proposed Sale	39.90	36,484	1,455,712		Dec 01 05:10 PM
Sandy Lamm LLC	Officer	Dec 01 '25	Proposed Sale	19.93	46,667	930,232		Dec 01 04:48 PM
Coyne Terrance P.	EVP & CFO	Nov 24 '25	Sale	38.55	69,582	2,682,505	51,010	Nov 26 05:01 PM
Terrance Coyne	Officer	Nov 24 '25	Proposed Sale	39.75	69,582	2,765,884		Nov 24 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	132,426	5,077,627	0	Nov 21 04:55 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	3,000	115,029	0	Nov 21 04:55 PM
George Lloyd	Officer	Nov 19 '25	Proposed Sale	38.65	355,426	13,737,215		Nov 19 05:41 PM
Coyne Terrance P.	EVP & CFO	Nov 17 '25	Sale	39.30	69,594	2,735,329	54,760	Nov 19 04:53 PM
Terrance Coyne	Officer	Nov 17 '25	Proposed Sale	39.16	69,594	2,725,301		Nov 17 05:38 PM
Norden Gregory	Director	Aug 11 '25	Sale	36.23	33,500	1,213,749	194,848	Aug 11 04:35 PM
Norden Gregory	Director	Aug 11 '25	Proposed Sale	36.23	33,500	1,213,747		Aug 11 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience